ABSTRACT Inhalation treatment may be less effective in the presence ofbronchoconstriction because of the reduced penetration of drugs into the airways. The effect of bronchoconstriction on the lung deposition and plasma pharmacokinetics of inhaled sodium cromoglycate was examined. Ten subjects attended the laboratory on three occasions. On the first occasion a bronchial provocation test was performed to determine the concentration of methacholine required to reduce the forced expiratory volume in one second (FEV,) by 20% (PC20). On the two subsequent occasions subjects inhaled either saline or their PC20 methacholine, followed five minutes later by an aerosol containing sodium cromoglycate and stannous phytate labelled with technetium-99m. Twenty minutes later a gamma emission lung scan was performed to determine the intrathoracic deposition of the nebulised aerosol. The central:peripheral (C : P) ratio of lung deposition was then calculated. Measurements of FEV, were made and blood samples taken for analysis ofplasma sodium cromoglycate concentration at intervals for four hours. Methacholine led to a 23-4% (SEM 0-6%) lower FEV, and a 2-8 times higher C : P ratio than those observed after saline. There was a direct correlation between log PC20 methacholine and the increase in the C: P ratio (r = 0-8 1). Despite these changes with methacholine, the plasma pharmacokinetics of inhaled sodium cromoglycate were not significantly different after methacholine and after saline, except that the maximum concentration achieved (Cmax) was increased. These observations suggest that the area of cromoglycate deposition and the anatomical site are less important in determining the plasma pharmacokinetics of cromoglycate than is the total dose delivered to the lung.
Introduction
In 1967 Howell and Altounyan first reported that inhaled sodium cromoglycate administered as a dry powder via a propeller device was efficacious in the treatment of chronic asthma.' Delivery of drugs for asthma directly to the airways introduces a degree of therapeutic selectivity by achieving a high local concentration ofdrug for the desired pharmacological effects with minimum systemic side effects.2 Inhalation treatment for patients with airways disease is not, however, without its problems. Good technique is necessary for optimal drug delivery from metered dose and dry powder inhalers, and specialised equipment is necessary for nebulised solutions. In addition, the degree of bronchoconstriction may reduce the penetration of drug into the more peripheral airways. ?5 Changes in bronchial blood flow or the presence of mucosal oedema or excess mucus may decrease the passage ofinhaled drugs to small airways, or alter drug clearance from their sites of deposition.
The introduction of a specific radioimmunoassay for sodium cromoglycate has made it possible to examine the pharmacokinetics of this drug.6 After inhalation of cromoglycate as a dry powder from a Spinhaler plasma drug concentrations increase rapidly to reach a peak at 10-20 minutes, followed by a 612 gradual decline. The rate ofthe decrease in serum drug concentrations is less than that seen after intravenous administration79 and the absorption of sodium cromoglycate from the bronchial mucosa is rate limiting. The fall in plasma cromoglycate concentrations is therefore determined by the rate of drug absorption from the airways (absorption rate limited or flip flop kinetics).7'9 Thus the plasma cromoglycate concentration at any time is determined by the amount of drug remaining in the lung-that is, the site of action. In 1973 Benson and coworkers'0 showed that when patients with airways obstruction inhaled sodium cromoglycate as a dry powder urinary excretion of unchanged drug correlated with peak inspiratory flow rate. Similarly, in non-asthmatic subjects with normal baseline airway calibre a single inhalation of sodium cromoglycate powder produced peak plasma concentrations and an area under the plasma concentration-time curve (AUC) that related directly to the flow rate used to inspire the drug.9"' It is well established that bronchoconstriction has a large effect on the distribution of inhaled drugs in the airways, causing more central deposition. 5 Benson et al ' and Neale et al 8 have suggested that absorption of sodium cromoglycate after inhalation occurs at two rates-possibly relating to absorption from two anatomical sites, alveoli and airways. As bronchoconstriction would influence the penetration ofthe drug to each ofthese sites we have investigated the influence of methacholine induced bronchoconstriction on the deposition of sodium cromoglycate aerosol within the lung and its relation to plasma drug pharmacokinetics in 10 atopic subjects.
Methods
The study was approved by the Southampton university and hospitals ethical committee and all subjects gave their written informed consent. Ten symptom free volunteers (five men and five women of mean age 23 (SEM 1) years) were studied outside the pollen season. Subjects had to have normal baseline lung function (FEV, > 90% of predicted), and a bronchoconstrictor response to inhaled methacholine at a concentration of 64 mg/ml or less. All subjects were atopic (a > 3 mm skin weal response to at least one common allergen) and none was a smoker or taking regular medication. Two subjects had mild seasonal asthma requiring occasional inhaled salbutamol (Nos 9 and 10) but were symptom free at the time of study, and eight had seasonal allergic rhinitis.
Subjects attended the laboratory on three occasions, separated by at least 10 days. On the first occasion two baseline measurements of FEV, were made five minutes apart and a mean value was calculated. A Richards, Haas, Simpson, Britten, Renwick, Holgate methacholine bronchial provocation test was then undertaken. Methacholine was administered as an aqueous aerosol generated from a starting volume of4 ml by an Inspiron Mini-neb nebuliser (Bard International Ltd, Sunderland) driven by compressed air at a flow rate of 9 I/min. Subjects inhaled five deep breaths from functional residual capacity (FRC) to total lung capacity (TLC) of the aerosol through a mouthpiece while wearing a noseclip.'2 Under these conditions the aerosol mass median particle diameter is 4-2 jm (Malvern HSD 2600 laser particle sizer, Malvern Instruments Ltd, Malvern, Worcestershire).
Three minutes after aerosol inhalation two further measurements of FEV, were made one minute apart, the maximum value being used for analysis. Increasing doubling concentrations of methacholine (0-03-64 mg/ml, non-cumulative) were administered at five minute intervals until the FEV, had fallen by 20% from the mean baseline value. The cumulative methacholine concentration that reduced FEV, by 20% of baseline (PC20) was derived by linear interpolation from the log concentration-response curves.
On the two subsequent visits subjects inhaled in random order saline (placebo) and the previously determined PC20 methacholine, and FEV, was measured before and at 5, 15, and 25 minutes after each inhalation. At 5 minutes, when the fall in FEV, had previously been shown to be maximum, ' 
Results
For all the subjects studied the geometric mean PC20
for methacholine was 23X6 mg/ml with a range of 0-85-82-3 mg/ml. Five subjects had a PC20 methacholine of 8 or less (geometric mean PC20 1 7, range 0 85-3-9 mg/ml), and five had values over 8 mg/ml (geometric mean PC20 40, range 27-82 mg/ml) (table 1) .
There was no significant difference between mean (SEM) baseline measurements of FEV, on the saline (4-21 (0-28) 1), and methacholine (4-20 (0-30) 1) study days. After administration of the saline aerosol there was no significant change in FEV, measured at 5, 15, and 25 minutes. After the PC,, methacholine dose mean FEV, had fallen by 23-4% (0 6%) from baseline values five minutes after challenge (p < 0-001) and it remained low at 15 minutes (23-9% (0-9%)). Inhalation of radiolabelled sodium cromoglycate aerosol caused no significant change in FEV, after either saline or methacholine when measured five minutes after administration. In all subjects bronchoconstriction after methacholine was associated with increased central and decreased peripheral deposition of radiolabelled cromoglycate aerosol, the geometric mean C P ratio being 0-68 (range 0 3-3-8) after saline and 1 87 (0 7-8 2) after methacholine (p < 0 005) (table 2) . A significant correlation was observed between the fold increase in C: P ratio and the previously determined log,0 PC20 methacholine (r = 0-81, p < 0.01) (fig 1) .
On the day that subjects inhaled saline followed by sodium cromoglycate---Tc labelled stannous phytate the plasma profile ofcromoglycate showed the characteristic absorption limited pharmacokinetics (fig 2) . The mean (SEM) pharmacokinetic indices were: Cmax 7 8 (1 0) ng/ml, AUC 1687 (266) ng/ml/ min, tmax 31 (8) min, initial t /2 5-4 (2 6) min, and terminal t ½/2 166 (35) min, (table 2). The plasma profile when cromoglycate was given after methacholine was not significantly different from that observed after inhaled saline with the exception of Cmax, which was significantly higher (10-6 (1 3) v 7 8 (1) ng/ml; p < 0 03) (fig 2) . No relationship could be established between any of the calculated indices of sodium cromoglycate pharmacokinetics and the starting methacholine responsiveness or the distribution pattern of aerosol within the lung. The pharmacokinetic data for subjects with a PC20 methacholine of 8 mg/ml or less did not differ significantly from those of subjects with a PC20 over 8 mg/ml, despite the much greater shift in C P ratio after methacholine in the latter group.
Discussion
The plasma pharmacokinetics of inhaled sodium cromoglycate administered as an aerosolised solution (in both normal and hyperresponsive asthmatic and non-asthmatic subjects) fits a simple, one compartment model in which the terminal decrease in plasma concentration is absorption rather than excretion limited.79"' A more complex model including two absorption rates to fit plasma concentration-time data 
Effect ofmethacholine induced bronchoconstriction on the pulmonary distribution andplasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways 615 after inhalation of sodium cromoglycate has been proposed recently by Neale et al, 8 but this was not found to be necessary for the analysis of the present pharmacokinetic data or for similar data obtained previously after inhalation of dry powder sodium cromoglycate.9 Reduction ofthe FEV, by over 20% by inhalation of methacholine before inhalation of a radiolabelled sodium cromoglycate aerosol greatly influenced the regional deposition of the drug in favour of the central airways. Surprisingly, however, this alteration in regional deposition produced no discernible effect on cromoglycate pharmacokinetics apart from a small but significant increase rather than decrease in Cmax.
The absorption of inhaled sodium cromoglycate from the bronchial mucosa is complex and may be an important determinant of its therapeutic efficacy in asthma. Neale et al8 studied the plasma kinetics of sodium cromoglycate after both intravenous dosing and inhalation from a spinhaler. The latter resulted in wide variation between individuals, and to fit the data to a pharmacokinetic model two absorption rates had to be incorporated. They suggested that the rapid and slow increases in plasma sodium cromoglycate they observed may relate to differing anatomical sites of drug absorption within the lung, the initial rapid absorption being from the alveolar capillary bed from small particles penetrating to the lung periphery and a slower phase representing absorption from the airways mucosa.'°If initial rapid absorption occurred through the alveoli then deposition of more aerosol in more central airways would be expected to diminish both the initial plasma half life of the drug and its maximum concentration and prolong the terminal half life, which is absorption rate limited. Despite the appreciable fall in FEVY, however, and the increased central deposition of sodium cromoglycate after inhalation of methacholine in the present study the initial plasma half life and the terminal half life were unchanged and the maximum concentration was increased rather than decreased. Moreover, in the absence and in the presence of bronchoconstriction the amount of cromoglycate being deposited in the lungs as reflected by the AUC was similar. These findings, and the observation that the plasma pharmacokinetics of inhaled sodium cromoglycate is almost identical after direct bronchoscopic instillation of the drug into a segmental bronchus,9 support the view that there is a single absorption compartment within the lung for cromoglycate. The high early plasma peak of sodium cromoglycate after inhalation of the dry powder described by Neale et al8 was not seen in this or our previous studies on cromoglycate pharmacokinetics.9 " The high early peak probably relates to the more rapid of the two absorption rates proposed by Neale et al.8 Its absence in the present study after saline inhalation when considerable peripheral aerosol deposition occurred is difficult to explain, but may indicate a difference in the permeability characteristics of the airways in different subjects.
In our study the total amount of sodium cromoglycate absorbed into the circulation, as reflected in the AUC, was not reduced when the drug was administered in the bronchoconstricted state. We interpret this as implying that the area ofcromoglycate deposition within the bronchial tree is not a major determinant ofits plasma pharmacokinetics following inhalation. Consequently sodium cromoglycate absorption from the lung periphery must contribute a negligible amount to the total amount of absorbed drug.
An unexpected finding was the significant positive correlation between PC20 methacholine, an index of non-specific airways responsiveness, and the increase in the central to peripheral ratio of radiolabelled aerosol deposition. Thus in those subjects with increased bronchial responsiveness the peripheral airways contribute more than the central to the reduction in FEV, induced by methacholine whereas the reverse is true of subjects with airways responsiveness falling within the normal range. McFadden and Lyons'4 have reported that peripheral airways in asthma are more responsive to cholinergic stimuli than are central airways, though whether this reflects a greater peripheral distribution in muscarinic cholinergic receptors'5 or increased smooth muscle receptorcontraction coupling is not known. It has been reported that the efficacy of aerosolised sodium cromoglycate in protecting against exercise provoked bronchoconstriction in asthma is related to the total plasma concentration of the drug (AUC) and therefore the total dose delivered to the lung. '6 If this relationship were to be extrapolated to the present study, the total dose ofcromoglycate reaching the lung would be the important determinant of efficacy rather than the pattern of distribution within the lung. Many asthmatic patients who use sodium cromoglycate for maintenance treatment of their disease have varying degrees of airways obstruction with attendant airflow limitation. In these conditions any drug delivered by inhalation is likely to be deposited in the central rather than the peripheral airways. As we have observed almost identical cromoglycate plasma pharmacokinetics irrespective of the state of bronchoconstriction, possibly cromoglycate deposited centrally is distributed peripherally via the bronchial circulation, which thus extends its area of pharmacological action within the bronchial tree. To establish whether this occurs in reality, further studies are required to relate sites of deposition of sodium cromoglycate to its protective effect against challenge and subsequently to clinical efficacy.
